$DH

Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates

Definitive Healthcare (DH) delivered earnings and revenue surprises of +16.67% and +1.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 7, 2025, 1:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 7, 2025, 3:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates — source image
Decision brief

The 30-second read

$DHBullishMed
01

Why it matters

The earnings beat suggests improved financial health, potentially leading to stock price appreciation.

02

Market read

The positive earnings report enhances DH's short-term trading prospects, especially within healthcare and technology sectors.

03

What to watch

Potential macroeconomic headwinds or sector-specific risks could offset positive earnings impact.

Timing: Immediate, as earnings reports influence short-term trading.

Background

Definitive Healthcare reported Q3 earnings that exceeded estimates, indicating operational strength.

Company-level read

Ticker impact

$DHBullishHigh confidence
Context

Primary focus of the news due to earnings beat.

Expected impact

Moderate upward movement expected in the short term.

Evidence & confidence

The earnings beat significantly exceeds analyst expectations, suggesting strong operational performance. The positive sentiment and historical market reactions to earnings surprises support this outlook.

Market effects

Positive sentiment for healthcare and technology sectors due to strong earnings.

Potential uplift in regional healthcare stocks; limited impact on broader markets.

Moderate, as healthcare sector performance can influence global health tech trends.

Counterpoint

Earnings beat may be a short-term anomaly; caution advised before overextending positions.

Key entities

  • Definitive Healthcare

    A healthcare analytics and data provider.

Related articles

$DHMedAI 8/10

Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

$DHHigh

Definitive Healthcare Corp. (DH): Results of Operations and Financial Condition

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dh-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Hea

$JNJMedAI 8/10

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson (JNJ) proposed a $5.5B settlement for 76,000 talc-related lawsuits, but it requires 95% claimant approval and may exceed this amount. The company has $21B in cash and expects to pay $3B in 2027, with further payments starting in 2028. A judge's recent ruling may strengthen JNJ's legal position. Investors weigh the benefit of reduced uncertainty against potential higher costs.

$CRWDMed

Analysts Back CrowdStrike, Dell and SanDisk Growth

Wall Street analysts maintain positive outlooks on CrowdStrike, Dell, and SanDisk, citing long-term growth in cybersecurity, AI infrastructure, and storage. CrowdStrike's price target raised to $245 by Truist, Dell's to $550 by Evercore, and SanDisk's to $2,250 by J.P. Morgan, all with buy ratings.

$PBRMed

Pemex and Petrobras Bet Big on High-Risk High-Reward Drilling Off Mexico

Pemex and Petrobras are collaborating to explore deep, high-risk oil prospects in the Gulf of Mexico. Pemex, facing declining production and high debt, seeks to unlock potential resources in Jurassic formations. Petrobras, with extensive pre-salt drilling experience, brings technical expertise. Success could reverse Pemex's fortunes, but risks remain high. Pemex reported a 70% net profit drop in Q2 2024, producing 1.66 million bpd, below government targets.